{
"id":"mk19_bb_hm_s19",
"subspecialtyId":"hm",
"title":"Hemophilia A and B",
"jsonContent":{
"type":"section",
"id":"mk19_bb_hm_s19",
"title":{
"__html":"Hemophilia A and B"
},
"titleNode":{
"type":"section-title",
"hlId":"f5854e",
"children":[
"Hemophilia A and B"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_hm_s19_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"40d903",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Factor VIII (hemophilia A) and factor IX (hemophilia B) deficiencies"
]
},
" "
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"4af195",
"children":[
"X-linked disorders seen almost exclusively in men"
]
},
" ",
{
"type":"list-item",
"hlId":"2b25e3",
"children":[
"consider in patients with a personal or family history of spontaneous, excessive posttraumatic or unexpected surgical bleeding"
]
},
" "
]
},
{
"type":"p",
"hlId":"7c748e",
"children":[
"Up to one third of patients with hemophilia A may develop factor VIII inhibitor antibody. The presence and quantity of inhibitor are measured with the Bethesda assay, and the level of the assay determines therapy."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s19_2",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"62ffa2",
"children":[
"The ",
{
"type":"abbreviation",
"title":"prothrombin time",
"children":[
"PT"
]
},
" is normal and the ",
{
"type":"abbreviation",
"title":"activated partial thromboplastin time",
"children":[
"aPTT"
]
},
" is prolonged in hemophilia A and B."
]
},
{
"type":"p",
"hlId":"2ba5db",
"children":[
" ",
{
"type":"alert",
"children":[
"The results of a mixing study will normalize in a patient with a factor deficiency but will remain abnormal if an inhibitor is present."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s19_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"e1a29f",
"children":[
"Factor VIII or factor IX replacement is indicated for patients with hemophilia A or B, respectively, and severe bleeding or hemarthrosis."
]
},
{
"type":"p",
"hlId":"989a30",
"children":[
"Patients with mild hemophilia A should be given desmopressin for acute bleeding or before undergoing minimally invasive procedures (e.g., dental procedures)."
]
},
{
"type":"p",
"hlId":"72931d",
"children":[
"Prophylactic factor replacement has been proven to reduce the incidence of arthropathy in patients with severe hemophilia."
]
},
{
"type":"p",
"hlId":"ca7424",
"children":[
"If factor VIII inhibitor is present in low quantities (<5 Bethesda units), factor VIII replacement can overcome the inhibitor and control bleeding."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s19_4",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"2ef406",
"class":"test",
"children":[
"A 57-year-old man has a large left-sided ecchymosis. The hemoglobin concentration is 8 g/dL, platelet count is 220,000/ÂµL, PT is 12 s, and aPTT is 67 s. The abnormal aPTT does not correct with a mixing study."
]
},
{
"type":"p",
"hlId":"126694",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For diagnosis, choose acquired factor VIII inhibitor."
]
}
]
}
]
},
"tablesContent":{
}
}